Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Core Points - Oncolytics Biotech Inc. received a delinquency notification from Nasdaq due to its ordinary shares closing below $1.00 for 30 consecutive business days [1][2] - The company has until August 12, 2025, to regain compliance with the minimum bid price requirement [1][2] - If the bid price reaches or exceeds$1.00 for at least 10 consecutive business days before the deadline, Nasdaq will confirm compliance [2] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an immunotherapeutic agent delivered intravenously [4] - Pelareorep has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer, inducing anti-cancer immune responses [4][5] - The company is conducting combination clinical trials with pelareorep and has received Fast Track designation from the FDA for its studies in metastatic breast cancer and pancreatic cancer [5]